Leiner Loratadine Success In 2004 Positions Firm For Further OTC Growth
This article was originally published in The Tan Sheet
Executive Summary
Leiner views its OTC sales growth during its first fiscal quarter as representative of the way the company is reshaping its current business strategy to focus more on nonprescription drugs
You may also be interested in...
Perrigo Moves In On Major Generic Firms With Agis Acquisition
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players
Perrigo Moves In On Major Generic Firms With Agis Acquisition
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players
Perrigo Moves In On Major Generic Firms With Agis Acquisition
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players